Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983428 | 1.00 | MAPK14 (0.71) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL5814702 | 0.78 | MAPK14 (0.68) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL5353405 | 0.78 | MAPK14 (0.68) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL828307 | 0.75 | MAPK14 (0.80) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL2896072 | 0.74 | MAPK14 (0.93) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4467211 | 0.74 | MAPK14 (0.93) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4466336 | 0.74 | MAPK14 (0.93) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7214778 | 0.74 | MAPK14 (0.59) | MAPK14CSNK1DMAPK13MAPK12MAPK11 | |
| SCHEMBL2848864 | 0.74 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5451895 | 0.73 | MAPK14 (0.61) | MAPK14CSNK1DMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224180-B1 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | MAPK14 21/4885CSNK1D 1173/4885MAPK13 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.